Transgene SA is a French biotechnology company that specializes in the development of therapeutic vaccines and immunotherapies for the treatment of cancer and infectious diseases. The company has developed a number of innovative technologies, including its proprietary Transgene Expression System (TES), which is used to create and deliver therapeutic proteins to target cells. Transgene SA has also developed a number of therapeutic vaccines and immunotherapies, including TG4010, which is currently in clinical trials for the treatment of non-small cell lung cancer.